189 related articles for article (PubMed ID: 10027412)
1. Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Am J Pathol; 1999 Feb; 154(2):543-51. PubMed ID: 10027412
[TBL] [Abstract][Full Text] [Related]
2. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
6. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence.
Ito T; Yamamoto S; Ohno Y; Namiki K; Aizawa T; Akiyama A; Tachibana M
Oncol Rep; 2001; 8(6):1221-4. PubMed ID: 11605036
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation in human prostatic tumor models.
Noordzij MA; van Weerden WM; de Ridder CM; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Am J Pathol; 1996 Sep; 149(3):859-71. PubMed ID: 8780390
[TBL] [Abstract][Full Text] [Related]
9. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer.
Segawa N; Mori I; Utsunomiya H; Nakamura M; Nakamura Y; Shan L; Kakudo K; Katsuoka Y
Pathol Int; 2001 Jun; 51(6):452-9. PubMed ID: 11422807
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
[TBL] [Abstract][Full Text] [Related]
12. Function and molecular mechanisms of neuroendocrine cells in prostate cancer.
Huang J; Wu C; di Sant'Agnese PA; Yao JL; Cheng L; Na Y
Anal Quant Cytol Histol; 2007 Jun; 29(3):128-38. PubMed ID: 17672372
[TBL] [Abstract][Full Text] [Related]
13. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells].
Song Y; Wu G; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464
[TBL] [Abstract][Full Text] [Related]
14. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.
Nakada SY; di Sant'Agnese PA; Moynes RA; Hiipakka RA; Liao S; Cockett AT; Abrahamsson PA
Cancer Res; 1993 May; 53(9):1967-70. PubMed ID: 8481896
[TBL] [Abstract][Full Text] [Related]
15. Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines.
Jongsma J; Oomen MH; Noordzij MA; Romijn JC; van Der Kwast TH; Schröder FH; van Steenbrugge GJ
Prostate; 2000 Jan; 42(1):34-44. PubMed ID: 10579797
[TBL] [Abstract][Full Text] [Related]
16. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft.
Kim D; Gregory CW; French FS; Smith GJ; Mohler JL
Am J Pathol; 2002 Jan; 160(1):219-26. PubMed ID: 11786415
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
19. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
[TBL] [Abstract][Full Text] [Related]
20. MnSOD drives neuroendocrine differentiation, androgen independence, and cell survival in prostate cancer cells.
Quiros-Gonzalez I; Sainz RM; Hevia D; Mayo JC
Free Radic Biol Med; 2011 Feb; 50(4):525-36. PubMed ID: 21056653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
